The recent commercialisation of the first disease-modifying drugs for Alzheimer's disease
emphasises the need for consensus recommendations on the rational use of biomarkers to …

There is poor knowledge about the clinical effects of Lewy body (LB) pathology in patients
with cognitive impairment, especially when coexisting with Alzheimer's disease (AD) …

Several advances in fluid and tissue-based biomarkers for use in Parkinson's disease (PD)
and other synucleinopathies have been made in the last several years. While work …

Cognitive impairment (CI) is a characteristic non-motor feature of Parkinson disease (PD)
that poses a severe burden on the patients and caregivers, yet relatively little is known about …

Clinical trials in dementia with Lewy bodies: the evolving c... : Current Opinion in Neurology
Clinical trials in dementia with Lewy bodies: the evolving concept of co-pathologies, patient …

Introduction Operationalized research criteria for mild cognitive impairment with Lewy
bodies (MCI‐LB) were published in 2020. The aim of this systematic review and meta …

Dementia with Lewy bodies (DLB) and Parkinson disease (PD) with and without dementia
are entities of a spectrum of Lewy body diseases. About 26.3% of all PD patients develop …

Recognizing multiple neuropathological entities in people with dementia improves
understanding of diagnosis, prognosis, and expected outcomes from therapies. Care for the …

Background Diagnosing Dementia with Lewy Bodies (DLB) remains a challenge in clinical
practice. The use of 123I-ioflupane (DaTscan™) SPECT imaging, which detects reduced …

Concomitant Alzheimer's disease (AD) pathology is a frequent event in the context of Lewy
body disease (LBD), occurring in approximately half of all cases. Evidence shows that LBD …